Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Invested Capital (2016 - 2025)

Historic Invested Capital for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $822.7 million.

  • Ani Pharmaceuticals' Invested Capital fell 158.0% to $822.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $822.7 million, marking a year-over-year decrease of 158.0%. This contributed to the annual value of $726.6 million for FY2024, which is 1007.97% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Invested Capital stood at $822.7 million, which was down 158.0% from $755.7 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Invested Capital registered a high of $835.9 million during Q3 2024, and its lowest value of $300.6 million during Q3 2021.
  • In the last 5 years, Ani Pharmaceuticals' Invested Capital had a median value of $705.1 million in 2023 and averaged $662.7 million.
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 13195.44% in 2022, then tumbled by 1007.97% in 2024.
  • Ani Pharmaceuticals' Invested Capital (Quarter) stood at $687.8 million in 2021, then rose by 1.9% to $700.9 million in 2022, then grew by 15.29% to $808.1 million in 2023, then decreased by 10.08% to $726.6 million in 2024, then grew by 13.22% to $822.7 million in 2025.
  • Its last three reported values are $822.7 million in Q3 2025, $755.7 million for Q2 2025, and $739.6 million during Q1 2025.